31 Venous thromboembolism VTE Deep vein thrombosis DVT VTE DVT DVT VTE VTE VTE VTE VTE VTE VTE VTE 31.1 VTE (Elastic stocking ES) (Intermittent pneumatic compression ICP) (Low dose unfractionated heparin LDUH) (Low molecular weight heparin LMWH) 31.1 VTE ES
IPC LDUH LMWH 325mg/ INR 5~10mg INR 2~3 5000 2 PTT VTE * *LMWH 1 20mg enoxaparin 40mg 12 30mg Deltaheparin 1 2500 3000 Nadroparin 2500 Tinzaparin 3500 4500 75 /kg/ 2300 [1] DVT PE 20 DVT 1 2 PE [2]
50 DVT 30 PE [2] 3100 16 DVT [1,2] VTE 14 VTE [3] VTE 55 12 VTE [4] VTE 81 84% 3 5 VTE 92 89 73 21 38% VTE 46 64 VTE 25 44 [4] 65 20 38 VTE [5] VTE 38% 66% 10 VTE 94% 75% [5] 1995 A [ ] 84 76 45 50 VTE 3 [6] VTE 33 VTE 87 50 [8] 30 VTE 48 [9] VTE VTE DVT
PE DVT gold standard [10] duplex FUT 92 DVT 55% DVT 45% duplex 39 98 13 92 [12] FUT DVT 25 19 FUT DVT 9 28 [2] VTE DVT DVT DVT gold standard [13] PE PE DVT 50 [14] VTE 31.2 31.2. DVT * DVT ES 44% 3 [2] 25% LDUH 68% 47 LMWH 76% 21 IPC 88% 2 [2] 54% LMWH 70% 30 warfarin 59% 13 64% LMWH 52% 13
[2,23] IPC 73% 6 [27,28] 28% LMWH 38% 3 LDUH 72% 1 [2,30] 30-60% LMWH 30% ( LDUH ) 1 [2] 80% LDUH 56% 5 [2] 55% LMWH 58% 3 Danaparoid 82% 4 [2] 16% LMWH 76% 2 39% 2 LDUH 61% 3 *DVT ES IPC LDUH LMWH THR TKR FUT( ) DVT VTE DVT 19 DVT 7 PE 1.6 PE 0.9 [2] VTE 40 DVT VTE [2] * DVT 80% 2% DVT 20% 0.4% PE 10% 0.2% PE 5% 0.002% * LDUH LMWH DVT PE
LDUH DVT 68 25 [2] LMWH VTE LDUH DVT PE LDUH [2,15,16] LMWH 3400 anti-xa units LMWH DVT IPC ES DVT DVT PE [17 20] THR VTE 1 DVT 54 DVT 25 PE 5 15 PE 1 2 PE 0.1 0.4 [2,21] THR VTE 52 LMWH LDUH IPC DVT [21] IPC ES DVT DVT [2,17] LMWH DVT 70 80 [2,21] LMWH LDUH IPC DVT [21] 5 DVT LMWH 3.4 4.8 [2] LMWH THR PE 0.16 LMWH.36 [21] IPC LDUH PE [21] PE LMWH 0.04 0.16 [21] VTE LDUH LMWH [2] DVT PE PE 4 12 THR LMWH VTE [2] LDUH VTE 0.5 [22] (TKR) THR DVT 64 DVT
15 DVT PE LMWH 29 DVT [23] IPC DVT DVT LMWH TKR DVT DVT 63 [2] LDUH TKR DVT [2] DVT 8 2 TKR VTE 0.8% [24] DVT 53 45 PE 12 8 IPC 17 6 TKR PE TKR PE [23] LMWH PE PE PE 1.3 0.4 11.7 8.2 IPC 0.5 6.3 [25] THR LMWH VTE (10% 15% p=0.02) LMWH (0.9% 3.5% p=0.01) DVT LMWH 35 DVT 75 66 14 27 DVT 66 4 12 [2]
DVT 22 DVT 5 [2] DVT DVT LMWH LMWH+ES ES DVT LMWH DVT 38 18 28 p=0.008 LMWH DVT 50 6% 12 p=0.008 LDUH FUT DVT LDUH DVT 82 6 34 p=0.005 [28] IPC VTE IPC DVT 66 7 18 22 p<0.001 [2,17] IPC DVT 6 17 p<0.001 VTE DVT 50 DVT 20 PE 2 [2] VTE [29] LDUH 4 OR=0.97 95 C2 0.35 2.6LDUH ES 3 0.77 95 CI 0.27 2.2 DVT DVT DVT LDUH LMWH enoxaparin DVT 30 31 44 p=0.01 [30] 265 PE 1 LMWH DVT 40 90 FUT DVT [2] VTE 81 DVT 35 DVT [31] VTE IPC DVT IPC 40 IPC+ + 25 [32] LMWH 1 3500U tinzaparin LDUH 3 5000U LMWH DVT 16 0 [33] 48 LMWH
13 DVT [34] 15 LMWH LDUH DVT [30] DVT DVT LMWH 50 0 LDUH 67 13 VTE 24 DVT LDUH DVT 71 [2] 55 DVT LDUH LMWH 10 14 DVT 56 55 24 [2] LDUH 5000 1 3 LMWH Enoxaparin1 40mg LMWH DVT [2] DVT 16 [2] DVT 56 PE 52 [35] LMWH LDUH DVT PE LMWH 0.48 95 0.23 1.00 [35] Enoxaparin 40mg 14 866 NYHA3 4 VTE 63 [36] DVT 65 1.7 4.9 RR=0.40 DVT DVT 110 Enoxaparin 20mg VTE [37] VTE VTE DVT 75 37.5 9.5 VTE LDUH LMWH IPC DVT LMWH LMWH LDUH
LMWH LMWH LDUH VTE VTE 31.3 LDUH LMWH VTE LDUH LMWH IPC DVT LMWH IPC LMWH LDUH DVT VTE VTE LMWH IPC LDUH LMWH VTE LDUH LMWH ES IPC 31.3. VTE * 40 LDUH, LMWH, ES IPC 40 60 40 60 LDUH, LMWH 60 40
LDUH LMWH ES VTE IPC 40 LMWH LMWH ES IPC LMWH 12 12-24 4-6 INR 2.0-3.0 LMWH LMWH IPC LDUH LMWH LMWH LMWH with ES or IPC ES IPC LMWH LMWH INR 2.5 LDUH, LMWH ES danaparoid IPC LDUH LWMH LDUH LMWH [15] LMWH LDUH
LHWH [16] VTE LDUH 3.4 0.56 RR=3.46 p 0.0001 LMWH absolute risk increase ARI TKR 2.9 0.9 ARI21.7% THR 1.2 0.9 ARI0.3% [21] TKR 0.5 LMWH Hb 2g/dl [2] LMWH LDUH [28] 24 enoxaparin30mg12 grade3 (grade4) enoxaparin [38] Enoxaparin1 40mg LDUH LMWH 0.48 95 0.23 1.00 [35] VTE LDUH LMWH LDUH LMWH [39] LDUH LMWH VTE Enoxaparin LDUH 1,000 12 145,667 [40] LDUH LMWH 2.6 LMWH 1000 50,000 TKR VTE LMWH LMWH THR LDUH DVT 200 LMWH DVT VTE 1 LMWH 12,000 1 3 LDUH LMWH 48mg Enoxaparin 1,000 10,753 20 Enoxaparin 15,000 [44] LDUH DVT DVT
DVT [45] CDSS [46] VTE VTE VTE